EuroBiotech: More Articles of Note


> Boehringer Ingelheim and Zealand Pharma moved dual-acting GLP-1/glucagon agonist BI 456906 into a phase 2 trial in diabetes and obesity. The start of the trial will trigger a €20 million ($22 million) milestone payment to Zealand. Release 

> UniQure’s pivotal hemophilia B gene therapy trial hit its enrollment target. UniQure plans to continue adding up to six patients throughout September, taking it above the target. Statement 

> Valo Therapeutics acquired oncolytic virus technology from the University of Helsinki. Release 


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> Macrophage Pharma named Søren Bregenholt as its CEO. Bregenholt previously held senior roles at Symphogen and IO Biotech. Statement 

> Gyroscope Therapeutics raised £50.4 million ($60.6 million) to fund clinical development of a dry age-related macular degeneration gene therapy. Syncona provided most of the money. Release (PDF)

Suggested Articles

Panelists at the CAR-TCR Summit reflected on gender diversity trends and the challenges women face in the life sciences industry.

Loh joins the computational chemistry specialist after a two-year stint at Kymera Therapeutics.

The $3 billion funding boost includes an additional $350 million for targeted Alzheimer’s research.